BiotechTube

Sintilimab + Nab paclitaxel + Cisplatin

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Esophageal Squamous Cell Carcinoma

Conditions

Esophageal Squamous Cell Carcinoma

Trial Timeline

Aug 31, 2020 → Dec 31, 2022

NCT ID
NCT04548440

About Sintilimab + Nab paclitaxel + Cisplatin

Sintilimab + Nab paclitaxel + Cisplatin is a phase 2 stage product being developed by CSPC Pharmaceutical Group Limited for Esophageal Squamous Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04548440. Target conditions include Esophageal Squamous Cell Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04548440Phase 2Completed

Competing Products

20 competing products in Esophageal Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
77
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
41
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
41
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
77
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
41
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPre-clinical
23
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
52
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPhase 1
33
FamotidineAstellas PharmaPhase 2/3
65
ASP546CAstellas PharmaPhase 1/2
41
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
41
JS001 + nab-paclitaxel + Cisplatin + CarboplatinSun PharmaceuticalPhase 2
52
E3810 + E3810 + PlaceboEisaiPhase 3
77
Rabeprazole ER + RanitidineEisaiPhase 3
77

Other Products from CSPC Pharmaceutical Group Limited

Butylphthalide + Butylphthalide placeboPhase 3
76
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsPhase 2
51
pegylated liposomal doxorubicin (PLD) + PD-1Phase 2
51
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabPhase 1/2
40